Business

Business

The Cigna Group is a US-listed ($76.5B market cap, NYSE: CI) global health company that runs two engines: Evernorth, one of the three national pharmacy-benefit managers, and Cigna Healthcare, a medical-benefits insurer. FY2025 revenue was $274.9 billion. It clears both universe lines — US common stock, market cap far above the $10B bar. It is not an auto maker and not a consensus darling: at 12.8x earnings it is the cheapest large managed-care name in its peer group.

What Cigna is, in two sentences

The Cigna Group sells two things. Through Evernorth Health Services it manages other payers' and employers' drug spend — negotiating prices, running mail-order and specialty pharmacies, and processing prescription claims at national scale; through Cigna Healthcare it sells and administers medical insurance, increasingly as a fee-based administrator of self-funded employer plans rather than a risk-taker. A global workforce of roughly 67,700 serves more than 185 million customer relationships across more than 30 markets, alongside about 1.7 million provider relationships [1].

The company was incorporated in Delaware in 1981 through predecessor insurers and renamed from Cigna Corporation to The Cigna Group in February 2023 [2] [3] — a long operating history that P1 durability leans on (Durability).

Source: FY2025 Annual Report (Form 10-K), Item 1 Business [4] and consolidated financials as reported; market cap at $284.85 on 2026-07-22 (fit_features.market_cap_usd).

The two engines — a large thin-margin pharmacy business and a smaller fat-margin insurer

The two segments are economically opposite. Evernorth is high-volume, low-margin: it books adjusted revenues of $234.9 billion (Pharmacy Benefit Services $132.1B plus Specialty and Care Services $102.8B) on pre-tax adjusted income of $7.2 billion — a 3.1% pre-tax margin — while processing 2,222 million adjusted scripts a year [5]. Cigna Healthcare is a quarter of Evernorth's revenue but earns a far richer margin: $47.2 billion of adjusted revenues at $4.15 billion pre-tax income — an 8.8% pre-tax margin, on a medical care ratio of 84.4% [6].

Source: FY2025 Annual Report (Form 10-K), MD&A — Evernorth p.80 [7] and Cigna Healthcare p.82 [8].

The result: Evernorth is 83% of segment revenue but only 64% of segment pre-tax income; Cigna Healthcare's smaller book carries the profit density. For a durability read, that matters — Evernorth's economics rest on scale and negotiating leverage in a pass-through business, while Cigna Healthcare's rest on underwriting and the medical-cost reserve that defines any managed-care income statement.

A second structural fact sits inside Cigna Healthcare: of 18.1 million medical customers — down 5% year over year after the 2025 exit of Medicare Advantage — 14.3 million (79%) are administrative-services-only, self-funded employer members on which Cigna earns a fee and bears no insurance risk; only 3.8 million (21%) are insured lives where Cigna holds the claims risk [9]. Cigna is, more than its peers, a fee-based administrator rather than a risk-bearer.

Where the revenue and the geography sit

By source, the top line is a pharmacy business with an insurance business attached: Evernorth generated $219.4 billion of pharmacy revenues in FY2025 against $39.7 billion of Cigna Healthcare premiums [10].

Source: FY2025 Annual Report (Form 10-K), Note 23 Segment Information — Revenue Disaggregation [11].

Geographically the business is overwhelmingly domestic. International Health premiums were about $4.1 billion — roughly 1.5% of total revenue — serving globally mobile individuals and local markets including China, Singapore, Hong Kong, Spain, India and the Middle East [12]. One nuance for the reader: pre-tax income from foreign operations was about 53% of consolidated pre-tax income in 2025 (62% in 2024, 48% in 2023) — a figure inflated by international tax structuring and by a 2024 US impairment that depressed domestic earnings, not by a foreign-heavy revenue base [13].

China exposure — a sensitivity flag, quantified and immaterial (S1)

Cigna's only material China footprint is a 50%-owned insurance joint venture accounted for by the equity method — it contributes no consolidated revenue. Cigna's 50% share of the joint venture's investment portfolio was about $18.2 billion, but that is the JV's own balance sheet, not Cigna's; on Cigna's books the China JV carried a negative value of about $(0.3) billion at year-end 2025 after accumulated other-comprehensive-loss adjustments [14]. China is one of several small International Health markets, not a revenue or asset dependence. Against Ruchir's S1 test — heavy China revenue/asset reliance — the flag is raised and cleared: exposure is immaterial, and CI is US common stock, not a Chinese ADR.

Market structure — the P1 raw material

Cigna operates in two concentrated markets, both with high regulatory entry barriers. This is the evidence the Durability tab and the jury will lean on.

Pharmacy benefits: a three-firm oligopoly. The three largest PBMs — CVS Caremark, Cigna's Express Scripts (Evernorth), and UnitedHealth's Optum Rx — together process roughly 80% of US prescription claims (FTC staff findings, 2024–25). The concentration is confirmed inside competitors' own filings: CVS's FY2025 10-K names "the Express Scripts business of Cigna Corporation" and "the Optum Rx business of UnitedHealth Group" as its principal PBM competitors, alongside smaller players Prime Therapeutics and MedImpact [15], and UnitedHealth's FY2025 10-K sizes Optum Rx at $188 billion of managed pharmaceutical spend — the same pool Evernorth's Express Scripts and Accredo compete for [16]. Evernorth's own scale — $219.4 billion of pharmacy revenues on 2,222 million adjusted scripts — places it firmly among the three [17].

Health benefits: a national oligopoly. The commercial and government managed-care market is dominated by a handful of scaled insurers — UnitedHealth, Elevance, CVS/Aetna, Cigna, Humana and Centene. After divesting Medicare Advantage to Health Care Services Corporation in March 2025, Cigna Healthcare is now the smaller, commercial-and-international tilt of that group, competing chiefly on self-funded employer accounts.

Source: CVS FY2025 10-K p.24 [18]; Cigna FY2025 10-K Regulation, p.35–37 [19]; PBM concentration per FTC staff findings (2024–25).

Regulatory entry barriers are real and named. Cigna's insurance and HMO subsidiaries must be individually licensed by each jurisdiction in which they operate [20]; they are subject to NAIC risk-based-capital minimums that trigger regulatory intervention if surplus falls short, and to guaranty-fund assessments for insolvent peers [21]; and their insured medical plans face ACA minimum medical-loss-ratio rebate requirements [22]. A garage start-up cannot take this share; capital, licensing and regulated reserves gate the market — the kind of barrier Ruchir's P1 durability test weighs. The counter-fact is that the same regulatory intensity now points at the PBM economics: in February 2026 the FTC reached a settlement with Express Scripts over rebate transparency, a live pressure on the durability of Evernorth's margin that Durability carries.

Universe and first-pass exclusion screen

On the exclusion checks this tab can settle: Cigna is a health-services and insurance company, so the auto-OEM exclusion (X1) does not apply. On darling positioning (X4), it is the opposite of a consensus-saturated name. At $284.85 against $22.18 of FY2025 EPS, Cigna trades at 12.8x earnings — the lowest positive multiple in its peer set — and at 0.28x sales.

Source: prices as of 2026-07-22 and FY2025 reported EPS/revenue, as reported; P/E and P/S derived. Centene P/E not meaningful (FY2025 net loss). Managed-care price/sales runs low sector-wide because pass-through pharmacy and premium revenue inflates the denominator; the P/E is the more telling darling gauge.

Two reads follow. First, low price-to-sales is not a Cigna signal — every managed-care name screens under 1x sales because pass-through revenue dwarfs profit, so P/S carries little information here. Second, on the more telling earnings multiple, Cigna sits below Elevance (15.4x) and far below UnitedHealth (32.6x) and Humana (40.4x) — though the latter two are elevated by depressed 2025 earnings, not by enthusiasm. There is no "changes-the-future" narrative, no high multiple-to-sales relative to peers, and no bottom-left-to-top-right chart; the whole sector is out of favor. X4 is not a hit. Whether that cheapness reflects a deserved de-rating or a dislocation is not this tab's question — the Dislocation, Damage Math and Yield tabs carry it. The promotional-CEO (X2) and structural-decline (X3) checks belong to Self-Help and Durability and are not duplicated here.